MyMD Pharmaceuticals, Inc. Stock price

Equities

MYMD

US62856X2018

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.39 USD +1.70% Intraday chart for MyMD Pharmaceuticals, Inc. -16.72% -69.20%
Sales 2021 - Sales 2022 - Capitalization 45.39M
Net income 2021 -29M Net income 2022 -15M EV / Sales 2021 -
Net cash position 2021 11.41M Net cash position 2022 4.69M EV / Sales 2022 -
P/E ratio 2021
-7.1 x
P/E ratio 2022
-2.94 x
Employees 10
Yield 2021 *
-
Yield 2022
-
Free-Float 3.15%
More Fundamentals * Assessed data
Dynamic Chart
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement MT
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split MT
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain CI
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023 CI
MyMD Pharmaceuticals, Inc.(NasdaqCM:MYMD) dropped from S&P Global BMI Index CI
Insider Buy: Mymd Pharmaceuticals MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
MyMD Pharmaceuticals Says Its Investigational New Drug Application for Rheumatoid Arthritis Treatment Gets FDA Acceptance MT
FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis CI
MyMD Pharmaceuticals' MYMD-1 Study Shows Positive Results for Age-Related inflammation Drug; Shares Rise MT
Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
MyMD Pharmaceuticals Says Phase 2 Trial of Treatment for Sarcopenia, Frailty Shows No Safety Issues MT
More news
1 day+1.70%
1 week-16.72%
Current month-30.32%
1 month-26.46%
3 months-67.84%
6 months-85.41%
Current year-69.20%
More quotes
1 week
2.23
Extreme 2.2301
2.75
1 month
2.23
Extreme 2.2301
3.60
Current year
2.23
Extreme 2.2301
8.70
1 year
2.23
Extreme 2.2301
70.50
3 years
2.23
Extreme 2.2301
298.50
5 years
2.23
Extreme 2.2301
298.50
10 years
2.23
Extreme 2.2301
298.50
More quotes
Managers TitleAgeSince
Director of Finance/CFO 51 21-04-14
President 71 20-10-31
Chief Tech/Sci/R&D Officer 57 20-12-17
Members of the board TitleAgeSince
Director/Board Member 58 17-08-07
President 71 20-10-31
Chairman 54 18-09-05
More insiders
Date Price Change Volume
24-03-28 2.39 +1.70% 32,983
24-03-27 2.35 +1.73% 10,308
24-03-26 2.31 -6.10% 36,768
24-03-25 2.46 -7.17% 37,787
24-03-22 2.65 -7.67% 41,563

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
More about the company
  1. Stock
  2. Equities
  3. Stock MyMD Pharmaceuticals, Inc. - Nasdaq